The eight‑year‑old Swedish start‑up Neko Health has secured $700mn from a mix of tech moguls, athletes and investors, led by existing backers Lightspeed Venture Partners and OG Venture Partners. The round values the company at almost $7bn, a fourfold jump from its January 2025 valuation.

Neko’s £299 preventive health checks—combining full‑body skin scans, blood analysis and in‑person consultations—have already reached over 100,000 patients in the UK and Sweden. After FDA approval of several products, founder Daniel Ek plans an aggressive rollout of new clinics in both the UK and the US, targeting a launch in New York later this year. All clinics older than six months are now profitable on a gross‑margin basis.

Ek, who stepped down as Spotify CEO in January, is applying Spotify’s playbook for international expansion, moving from Sweden to the UK and now tackling the US, the world’s largest healthcare market. The funding gives Neko a competitive edge against rivals like Function Health and Prenuvo, while bolstering its AI‑hardware integration strategy.